FFG
CRSP icon

Forum Finance Group’s CRISPR Therapeutics CRSP Stock Holding History

Forum Finance Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Buy
750
+500
+200% +$26.4K 0.01% 251
2026
Q1 		$10K Buy
+250
New +$13.2K 0.01% 274

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Forum Finance Group's CRSP Position: Q2 2026 in Review

Forum Finance Group increased its CRISPR Therapeutics (CRSP) stake by 200% in Q2 2026, buying an estimated $26.4K and bringing the position to 750 shares worth $33K. The position accounts for 0.01% of the portfolio, ranked #251.

Forum Finance Group first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Forum Finance Group held 750 shares of CRISPR Therapeutics worth $33K as of Q2 2026.
  • Forum Finance Group bought 500 CRISPR Therapeutics shares in Q2 2026, an estimated $26.4K.
  • CRISPR Therapeutics made up 0.01% of Forum Finance Group's portfolio in Q2 2026, its #251 holding.
  • Forum Finance Group first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Forum Finance Group's 13F filing for Q2 2026, filed 14 Aug 2026.